Aquestive Therapeutics (NASDAQ:AQST) resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for Anaphylm (dibutepinephrine) sublingual film, a treatment candidate for Type I allergic reactions including anaphylaxis.
Aethlon Medical (NASDAQ:AEMD) and North Immunology entered a definitive all-stock merger agreement that will combine the companies around NOR-101, a half-life extended IL-13 x IL-18 bispecific antibody being developed for atopic dermatitis and other immune-mediated diseases.
Sanofi (NASDAQ:SNY) and Cheplapharm announced plans to create a strategic partnership under which Cheplapharm would acquire a portfolio of 20 mature medicines and three manufacturing sites from Sanofi, with Sanofi receiving a 26.4% equity stake in Cheplapharm.
111 (NASDAQ:YI) received an unsolicited, preliminary and non-binding proposal from a buyer group to acquire all outstanding Class A ordinary shares not already owned by the group and take the company private.
Innate Pharma (NASDAQ:IPHA) reported revenue and other income of €5.7 million for the first half of 2026, while posting a net loss of €19.6 million as the biotechnology company adjusted its research and development activities.
IDEXX Laboratories (NASDAQ:IDXX) announced an expansion of its Faecal Dx™ antigen testing platform in the United Kingdom to detect taeniid tapeworms, including Taenia and Echinococcus species, adding another parasite group to its veterinary testing offering.
Sunshine Biopharma (NASDAQ:SBFM) advanced its lead coronavirus PLpro inhibitor into IND-enabling studies after preclinical testing showed antiviral activity against SARS-CoV-2 variants.
Twist Bioscience (NASDAQ:TWST) entered an agreement with Lilly TuneLab, an artificial intelligence and machine learning drug discovery platform created by Eli Lilly (NYSE:LLY), to provide antibody characterization data services.
Adagio Medical (NASDAQ:ADGM) announced the first patient treated in a clinical study evaluating its next-generation vCLAS Ultra Ultra-Low Temperature Ablation system for sustained monomorphic ventricular tachycardia.
Novo Nordisk (NYSE:NVO) and Anthropic announced a collaboration to apply Anthropic’s Claude AI models, including Claude Science, across Novo Nordisk’s research and development and software engineering activities.
Artelo Biosciences (NASDAQ:ARTL) reported nonclinical study results showing its ART27.13 compound produced approximately 20% body-weight loss over four weeks in obese mice, similar to semaglutide monotherapy.
IDEXX Laboratories (NASDAQ:IDXX) acquired CoVetAI, a provider of AI-powered ambient listening and clinical workflow software for veterinary practices worldwide.
